Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Benign Prostatic Hypertrophy Clear all
Completed Phase 3 Interventional Results available

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT00670306
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix Pamoate
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
56
States / cities
Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Sep 21, 2026, 8:48 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

NCT04879940
View directory record Official record
Conditions
Prostate Carcinoma, Benign Prostatic Hyperplasia
Interventions
Merit Medical Embospheres, Radiation Therapy
Device · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 3 Interventional Results available

A Study in Benign Prostatic Hyperplasia

NCT01152190
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Garden City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00384930
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 21, 2026, 8:48 AM EDT
Not yet recruiting Phase 4 Interventional

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

NCT06710327
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tranexamic Acid (IV), Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

5-Alpha Reductase and Anabolic Effects of Testosterone

NCT00475501
View directory record Official record
Conditions
Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
Interventions
Testosterone Enanthate, Finasteride, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT03055624
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Embosphere microparticles for prostate artery embolization
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

NCT04103450
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
31
States / cities
Huntsville, Alabama • Lincoln, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 21, 2026, 8:48 AM EDT
Completed No phase listed Observational Results available

Real World Data on Management of Male LUTS

NCT03075449
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 21, 2026, 8:48 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

NCT03179228
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Prostate Embolization
Device
Lead sponsor
John D Louie
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

NCT01438775
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Huntsville, Alabama • Atherton, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Not applicable Interventional Results available

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

NCT02026908
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Prostate Artery Embolization
Device
Lead sponsor
Northwestern University
Other
Eligibility
45 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 3 Interventional Results available

Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily

NCT00827242
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Placebo, tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Huntsville, Alabama • Middlebury, Connecticut • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Early Phase 1 Interventional

Ultrasound-Guided Photoselective Vaporization of the Prostate

NCT02346500
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Transrectal Ultrasound
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Not applicable Interventional

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

NCT02167919
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Microspheres
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 21, 2026, 8:48 AM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

NCT00759135
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Interventions
2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years to 75 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 21, 2026, 8:48 AM EDT
Recruiting Not applicable Interventional

A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms

NCT06849258
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
FloStent, Sham (Control)
Device
Lead sponsor
Rivermark Medical
Industry
Eligibility
45 Years and older · Male only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 3 Interventional

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

NCT00540891
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
ALFUZOSIN
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Male only
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 7, 2007 · Synced Sep 21, 2026, 8:48 AM EDT
Terminated No phase listed Observational

Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

NCT02019030
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Loma Linda, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 21, 2026, 8:48 AM EDT
Withdrawn Phase 4 Interventional

Role of Prophylactic Postoperative Antibiotics in HoLEP

NCT05274672
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions
Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 3 Interventional

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

NCT01966614
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
PRX302, Placebo
Drug · Other
Lead sponsor
Sophiris Bio Corp
Industry
Eligibility
50 Years and older · Male only
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 21, 2026, 8:48 AM EDT
Completed No phase listed Observational Results available

Flexiva Pulse Registry

NCT05027971
View directory record Official record
Conditions
Urinary Calculi, Benign Prostatic Hyperplasia
Interventions
Flexiva Pulse High Power Single-Use Laser Fibers
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 21, 2026, 8:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

NCT00537654
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 21, 2026, 8:48 AM EDT